

## Excelra releases COVID-19 biomarker database

12 June 2020 | News

**This resource is excerpted from Excelra's GOBIOM platform**

Hyderabad based Excelra, a leading global data-analytics company has announced the release of the COVID-19 Biomarker Database (<https://www.excelra.com/covid-19-biomarker-database/>) in support of the ongoing global scientific efforts, aimed at developing safe and effective therapeutic options to treat the novel coronavirus disease.

This resource is excerpted from Excelra's GOBIOM platform - the world's largest biomarker intelligence database. With reference to this endeavour, Dr. Raveendra Dayam, Director, Chemistry and Biology Data Services, Excelra, said, "The COVID-19 Biomarker Database is a compilation of manually curated biomarkers from published clinical trials, evaluating potential drugs or biologics for the treatment of SARS-CoV-2. The database additionally includes information on FDA-NIH recommended BEST (Biomarkers, Endpoints and other Tools) classification of biomarkers, supported with referenced literature."

The information in the COVID-19 Biomarker Database is presented in a user-friendly online application and the data is regularly updated with new biomarkers from clinical trials published in [clinicaltrials.gov](https://clinicaltrials.gov).

Excelra's GOBIOM is the world's largest manually curated database of validated and putative biomarkers, providing a comprehensive overview of the biomarker-disease relationship. Integrated with information encompassing the exploratory, preclinical and clinical domains, the database provides critical insights into diagnosis, prognosis, treatment response, safety, efficacy and toxicity. As a one-stop source for biomarker intelligence, GOBIOM enables informed clinical and therapeutic decision making to accelerate drug development.